[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456269":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":29,"studyPopulation":30,"armGroups":31,"interventions":42,"overallOfficials":26,"centralContacts":52,"locations":58,"responsibleParty":75,"collaborators":26,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":26,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":26,"studyType":91,"phases":26,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":61,"whyStopped":26,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Guangxi Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Recurrence-free survivial","Recurrence-free survival is calculated from the date of liver resection to the date of tumor recurrence or death from any cause, whichever occurred first.","1 year",[14],{"measure":15,"description":16,"timeFrame":12},"Overall survival","Overall survival is calculated from the date of liver resection to the date of death from any cause or the date of the last follow-up.",[18,21,23,24],{"measure":19,"description":11,"timeFrame":20},"Recurrence-free survival","3 years",{"measure":19,"description":11,"timeFrame":22},"5 years",{"measure":15,"description":16,"timeFrame":20},{"measure":15,"description":16,"timeFrame":22},{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":27,"timePerspective":28,"maskingInfo":26},null,"COHORT","PROSPECTIVE","Hepatic resection is one of the curative treatment for patients with early stage hepatocellular carcinoma (HCC) or selected intermediate or advanced disease. However, the postoperative 5-years recurrent rate is up to 70%, for whom recurrence is a major cause of death. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC by official guidelines. At the same time, four randomizead controlled trials about adjuvant immune checkpoint inhibitors for postoperative HCC are ongoing. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for such patients in clinical practice was reported. Therefore, the investigators plan to investigate the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with high-risk factor of HCC recurrence after curative hepatectomy in a prospective cohort study with real word clinical data.","Patients with hepatocellular carcinoma who underwent curative hepatectomy. And then, these patients receive adjuvant immune checkpoint inhibitors therapy or active surveillance.",[32,37],{"label":33,"type":26,"description":34,"interventionNames":35},"Immune checkpoint inhibitors based adjuvant therapy","Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.",[36],"Drug: Immune Checkpoint Inhibitors Based Adjuvant therapy",{"label":38,"type":26,"description":39,"interventionNames":40},"Without adjuvant therapy","Patients in this arm will not receive any adjuvant therapy.",[41],"Other: Active surveillance",[43,48],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":26},"DRUG","Immune Checkpoint Inhibitors Based Adjuvant therapy","Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy",[33],{"type":6,"name":49,"description":50,"armGroupLabels":51,"otherNames":26},"Active surveillance","Patients in this group only receive active surveillance",[38],[53],{"name":54,"role":55,"phone":56,"phoneExt":26,"email":57},"Jian-Hong Zhong, PhD","CONTACT","+86 15296561499","zhongjianhong@gxmu.edu.cn",[59],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Jian-Hong Zhong","RECRUITING","Nanning","Guangxi","530021","China","CN",{"type":68,"coordinates":69},"Point",[70,71],108.31667,22.81667,{"lat":71,"lon":70},[74],{"name":54,"role":55,"phone":56,"phoneExt":26,"email":57},{"type":76,"investigatorFullName":60,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Guangxi Medical University Cancer Hospital","100456269","adjuvant-immune-checkpoint-inhibitors-in-postoperative-hepatocellular-carcinoma-100456269",false,"NCT05221398","Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma","Adjuvant Immune CheckPoint InhibitoRs Based ThErapy in PostoperatiVe HEpatocellular CarciNoma: a ProspecTive Real-world Study","Inclusion Criteria:\n\n* Underwent curative hepatectomy;\n* Diagnosis of HCC was confirmed by postoperative histopathology;\n* Liver function Child-Pugh A or B;\n* Performance status score 0 or 1\n* With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion;\n\nExclusion Criteria:\n\n* Receive neoadjuvant immune checkpoint inhibitors therapy.","ALL","18 Years","75 Years",{"count":89,"type":90},10000,"ESTIMATED","OBSERVATIONAL","Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.",[94],"Hepatocellular Carcinoma",[96,97],"immune checkpoint inhibitor","adjuvant","2026-10-03",{"date":100,"type":101},"2026-10-07","ACTUAL",{"date":103,"type":101},"2019-03-03",{"date":105,"type":90},"2030-12-30",{"name":5,"class":6},1]